Il Yang Dapagliflozin Extended Release Tablets 5/500 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Il Yang Pharmaceutical Co., Ltd.
MFDS item code 202204067 · Approved 2022.11.10
Improves glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with type 2 diabetes by combining dapagliflozin and metformin. It is administered to adult patients whose blood sugar is not sufficiently controlled in conjunction with dietary and exercise therapies. Additionally, caution is warranted for patients with cardiovascular disease or risk factors for cardiovascular events. Using this medication with appropriate management can effectively improve blood sugar control.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients who have not previously received pharmacologic treatment for diabetes and for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or the nearest appropriate therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because changes may affect glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the eGFR falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).
This medication is used for diabetes treatment and should not be administered to patients with impaired kidney function. It may cause a rare side effect known as severe lactic acidosis, so it is important to regularly monitor kidney function and overall health. There is a risk of hypoglycemia when used in combination with insulin or sulfonylureas, so blood sugar changes should be carefully observed when these medications are used together. This medication should not be used in situations that may affect kidney function, such as dehydration, severe infections, cardiovascular issues, or acute myocardial infarction. In cases involving surgical procedures or radiological examinations that may burden the kidneys, the medication should be temporarily discontinued and resumed only after kidney function has normalized. Women who are pregnant or breastfeeding should not use this medication, and it should be administered to children and the elderly with caution. This medication can cause decreases in blood volume, hypotension, and changes in kidney function, so regular monitoring is necessary, especially for elderly patients or those with weakened kidney function. While taking this medication, there may be an increased risk of genital and urinary tract infections, and any signs of infection should be immediately discussed with healthcare professionals. This medication can lower vitamin B12 levels; therefore, it's advisable to monitor vitamin B12 concentrations during long-term use. Excessive alcohol consumption can increase the risk of side effects associated with this medication, so alcohol should be avoided while taking it. When using this medication with others, be cautious of the potential for drug interactions and inform healthcare providers about all medications being taken. This medication does not significantly affect driving or operating machinery, but caution is needed as dizziness may occur. Store out of reach of children, and keep it in its original container to prevent misuse or degradation of quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture and should be stored in a sealed container. To maintain the drug's efficacy, it is best to store it at room temperature, between 1 to 30 degrees Celsius.
Orange-colored, double-convex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Il Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.